In an interview with CNBC, FDA Commissioner Marty Makary defended the recent changes in the regulation of drugs for rare diseases.[5] Vinay Prasad, one of his senior representatives, announced to his team that the FDA would change its annual framework for flu vaccines and update the vaccine labels to be "sharpened".[1] The FDA will no longer approve vaccines for pregnant women without stricter requirements, and manufacturers of pneumonia vaccines will have to show that they reduce the incidence of the disease, rather than showing that they produce antibodies.[1] Makary also questioned the administration of multiple vaccines at the same time, which is still standard practice.[1] The agency faces personnel problems, including a high number of employee departures and instability in the management of individual departments.[5] Makary defends his approach as an effort to reform and partner with the pharmaceutical industry to achieve better treatment options.[3]